Status:
COMPLETED
Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Background: According to recent estimates, the prevalence of Chronic Hepatitis C (CHC) in Canada is three times more common in First Nations (FN)and Metis compared to non-FN populations. Moreover, on...
Detailed Description
Specific Objectives: 1. To provide detailed information on the demographics and clinical characteristics of treatment-naïve FN and Metis versus non-FN and Non-Metis patients proceeding to treatment f...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult patients of FN and metis and non-FN descent referred for treatment at the three centres will be candidates for this study.
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2012
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00957866
Start Date
May 1 2009
End Date
November 1 2012
Last Update
May 16 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Manitoba
Winnipeg, Manitoba, Canada, R3E 0W3
2
University of Regina
Regina, Saskatchewan, Canada
3
University of Saskatchewan
Saskatoon, Saskatchewan, Canada